Nursing care
Bisphosphonates: what to check before you give it
Written and reviewed by Dana Whitfield, RN, MSN · 5 min read · Updated September 2026
Short answer
Bisphosphonates such as alendronate and risedronate slow bone breakdown by inhibiting osteoclast activity, treating and preventing osteoporosis. The defining nursing point is administration: taken on an empty stomach with a full glass of plain water, then the patient stays upright for at least 30 minutes and eats nothing before that time passes, because the drug is caustic to the oesophagus and can cause erosion if it lingers there.
What it does and why it is prescribed
Bisphosphonates — alendronate, risedronate, ibandronate orally, zoledronic acid intravenously — bind to bone mineral and inhibit osteoclast-mediated bone resorption. Slowing that breakdown allows bone formation to outpace resorption over time, which increases bone density and reduces fracture risk.
They are prescribed for osteoporosis, for osteopenia with elevated fracture risk, for Paget's disease of bone, and for hypercalcaemia of malignancy or bone metastases where excessive resorption is releasing calcium into the blood. Oral agents are typically dosed weekly or monthly; intravenous zoledronic acid may be given yearly for osteoporosis or more frequently for malignancy-related indications.
Nursing considerations before giving it
Confirm renal function before administration, since these drugs are renally cleared and are generally avoided or dose-adjusted at significantly reduced eGFR. Check serum calcium and correct any pre-existing hypocalcaemia first — bisphosphonates lower calcium further by suppressing resorption, and giving them into an already low calcium state risks worsening it.
Ask about swallowing difficulty, active oesophageal disease, oesophageal stricture or delayed gastric emptying, all of which are reasons to avoid oral bisphosphonates because the tablet needs to clear the oesophagus quickly and completely. Confirm the patient can remain upright for the required period after dosing — this rules out bisphosphonates for a patient who is bed-bound or cannot sit or stand unassisted. For dental work, note that invasive procedures are ideally completed before starting therapy, given the rare risk of osteonecrosis of the jaw.
What to monitor
Monitor serum calcium and vitamin D status, since adequate calcium and vitamin D intake is usually required alongside therapy and hypocalcaemia can develop or worsen if intake is insufficient. Renal function is monitored periodically, particularly with intravenous dosing, which carries a more direct risk of nephrotoxicity than oral formulations.
Ask specifically about heartburn, chest pain, pain or difficulty on swallowing, and retrosternal discomfort at follow-up, since these point to oesophageal irritation or erosion developing from the medication itself. With long-term use, monitor for unusual thigh or groin pain, which can be an early sign of atypical femoral fracture, and for any new jaw pain, swelling or exposed bone suggesting osteonecrosis of the jaw.
Side effects versus adverse effects
Expected side effects include mild gastrointestinal upset, heartburn, and an acute phase reaction after intravenous dosing — flu-like symptoms, fever, myalgia — typically self-limiting and managed with antipyretics. These are common and rarely a reason to discontinue therapy outright.
The adverse effect the administration instructions exist to prevent is oesophageal erosion or ulceration, caused by the tablet remaining in contact with the oesophageal lining rather than passing quickly into the stomach — this is a direct chemical injury, not a rare idiosyncratic reaction. Other serious but less common adverse effects include osteonecrosis of the jaw, most associated with dental extractions or invasive procedures during therapy, atypical femoral fractures with long-term use, and hypocalcaemia significant enough to cause tetany or cardiac effects.
What to hold for and when to call
Hold the dose and notify the prescriber if the patient reports new or worsening heartburn, chest pain, or pain or difficulty swallowing — these suggest oesophageal irritation and continuing the drug risks progression to erosion or ulceration. Hold for any symptoms of hypocalcaemia, including perioral tingling, muscle cramps or tetany, and recheck calcium before the next dose.
Hold and call for unexplained new thigh, hip or groin pain in a patient on long-term therapy, since this can precede an atypical femoral fracture and warrants imaging before continuing. Call before any planned dental extraction or invasive oral surgery so the prescriber can weigh timing against osteonecrosis risk, and hold intravenous dosing if renal function has declined significantly since the last dose.
Patient teaching
Teach the administration sequence precisely, since it is the single most important thing to get right with oral bisphosphonates: take first thing in the morning on an empty stomach with a full glass of plain water, not juice, coffee or mineral water, which reduce absorption. Then stay fully upright — sitting or standing, not lying down — for at least 30 minutes, and eat or drink nothing else, including other medications, until that time has passed. This sequence exists to move the tablet through the oesophagus quickly and protect the lining from erosion, not primarily to improve absorption.
Teach patients to report heartburn, chest pain or swallowing difficulty rather than pushing through it, and to maintain adequate dietary calcium and vitamin D as advised. Mention weight-bearing exercise as a complementary measure for bone health, and advise informing any dentist of bisphosphonate use before extractions or implant surgery. For patients on long-term therapy, explain that new thigh or groin pain should be reported promptly rather than dismissed as routine musculoskeletal discomfort.
The next step on this is the same as on everything else here: answer questions and read the rationales. Our pharmacology practice questions are the closest set to what this page covers.
One question from the pharmacology set
A client with heart failure is started on furosemide 40 mg PO daily. Which findings should the nurse report to the provider before administering the next dose? Select all that apply.
Rationale
Furosemide is a loop diuretic, so the two things you are watching are potassium and kidney function. A potassium of 2.9 mEq/L is below the 3.5–5.0 reference range and puts the client at risk for dysrhythmia — hold and report. Muscle cramps with palpitations are the clinical face of that same hypokalemia, so they are reported together, not separately. A creatinine that doubles signals the diuresis has outrun renal perfusion. A blood pressure of 132/78 and a 1 kg loss are the expected response to the drug working, not reasons to hold it.
Answer: A, D, E
Common questions
Why must a patient stay upright after taking a bisphosphonate?
The tablet is caustic to the oesophageal lining if it lingers there, so staying upright for at least 30 minutes uses gravity to help it pass quickly into the stomach. This is about preventing oesophageal erosion, not about improving how much of the drug is absorbed.
Can bisphosphonates be given to a patient with low calcium?
No — hypocalcaemia should be corrected before starting therapy, because bisphosphonates further suppress bone resorption and can lower calcium further. Check serum calcium first and treat any deficiency before the first dose.
What is osteonecrosis of the jaw and who is at risk?
It is death of jaw bone tissue, most strongly associated with invasive dental procedures such as extractions during bisphosphonate therapy, particularly with long-term or intravenous use. Patients should have major dental work completed before starting therapy where possible, and inform their dentist of bisphosphonate use.
Why do bisphosphonates need to be taken with plain water only?
Coffee, juice, and mineral water all reduce absorption of the drug and can also increase gastric irritation, so plain water is specified to keep the medication effective and to avoid adding to oesophageal irritation risk.
What is an atypical femoral fracture and how does it relate to bisphosphonates?
It is an unusual fracture pattern in the femoral shaft, sometimes preceded by weeks of thigh or groin pain, occurring more often with long-term bisphosphonate use. Any new thigh, hip or groin pain in a patient on extended therapy should be reported and investigated rather than assumed to be routine strain.
More on pharmacology
Guides on this